TORC News and Press, resTORbio Inc. From 03/12/20

BOSTON, March 12, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results...

BOSTON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that the company will present at the 9th Annual L...

Nano cap resTORbio ( TORC +12.4% ) is up on increased volume in reaction to preliminary data from a Phase 1b/2a clinical trial evaluating lead candidate RTB101, with or without sirolimus (Pfizer's Rapamune ), in Parkinson's disease (PD) patients. More news on: resTORbio, Inc., Healthc...

-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in preclinical models to inhibit the activity of TORC1 and induce autophagy in neuronal cells --...

Neovasc (NASDAQ: NVCN ) +121%   files U.S. application for Reducer. More news on: Neovasc Inc., FuelCell Energy, Inc., Sol-Gel Technologies Ltd., Stocks on the move, Read more ...

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

BOSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that management will present at two upcoming inve...

Last week I wrote an article on AnaptysBio, Inc. (NASDAQ: ANAB ) after it got hammered down to over $100 million below its net cash value due to a failed clinical trial. The stock has since marginally recovered and I expect that to continue as it is still trading about $4 per share below net...

Karuna Therapeutics (NASDAQ: KRTX ) +80%  on positive KarXT data . More news on: Karuna Therapeutics, Inc., Eros International Plc, Capstone Turbine Corporation, Stocks on the move, Read more ...

Gainers:  Akerna (NASDAQ: KERN ) +47% . More news on: Akerna Corp., Mmtec, Inc., Melinta Therapeutics, Inc., Stocks on the move, Read more ...